Brown, Lisle/Cummings’s United Therapeutics UTHR Stock Holding History

Brown, Lisle/Cummings’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17K	Buy	4 +2	+100%	+$1.13K	﹤0.01%	839
2026 Q1	$1.19K	Buy	+2	New	+$996	﹤0.01%	914

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Brown, Lisle/Cummings's UTHR Position: Q2 2026 in Review

Brown, Lisle/Cummings increased its United Therapeutics (UTHR) stake by 100% in Q2 2026, buying an estimated $1.13K and bringing the position to 4 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Brown, Lisle/Cummings first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Brown, Lisle/Cummings held 4 shares of United Therapeutics worth $2.17K as of Q2 2026.
Brown, Lisle/Cummings bought 2 United Therapeutics shares in Q2 2026, an estimated $1.13K.
United Therapeutics made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #839 holding.
Brown, Lisle/Cummings first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.